Stratification by Risk Factors Predicts Survival on the Active Treatment Arm in a Randomized Phase II Study of Interferon-Gamma Plus/Minus Interferon-Alpha in Advanced Renal Cell Carcinoma (E6890) (Q47599414)

From Wikidata

Jump to navigation Jump to search

scientific article published on January 1, 2003

Language	Label	Description	Also known as
English	Stratification by Risk Factors Predicts Survival on the Active Treatment Arm in a Randomized Phase II Study of Interferon-Gamma Plus/Minus Interferon-Alpha in Advanced Renal Cell Carcinoma (E6890)	scientific article published on January 1, 2003

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/14514977

Stratification by Risk Factors Predicts Survival on the Active Treatment Arm in a Randomized Phase II Study of Interferon-Gamma Plus/Minus Interferon-Alpha in Advanced Renal Cell Carcinoma (E6890) (English)

1 reference

10.1385/MO:20:3:271

https://api.crossref.org/works/10.1385/MO:20:3:271

15 March 2024

renal cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

10.1385/MO:20:3:271

https://api.crossref.org/works/10.1385/MO:20:3:271

15 March 2024

Janice P Dutcher

1

object named as

Janice P Dutcher

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/14514977

author name string

Jason P. Fine

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:14514977

15 March 2024

Robert L. Krigel

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:14514977

15 March 2024

Barbara A. Murphy

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:14514977

15 March 2024

Paul L. Schaefer

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:14514977

15 March 2024

Marc S. Ernstoff

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:14514977

15 March 2024

Patrick J. Loehrer

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:14514977

15 March 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14514977

15 March 2024

publication date

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/14514977

full work available at URL

http://www.springerlink.com/index/pdf/10.1385/MO:20:3:271

1 reference

10.1385/MO:20:3:271

https://api.crossref.org/works/10.1385/MO:20:3:271

15 March 2024

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/14514977

20

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/14514977

3

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/14514977

271-281

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/14514977

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha and survival in renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon treatment of renal cell carcinoma. Current status and future prospects

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2003.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exact significance testing to establish treatment equivalence with ordered categorical data

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved prognostication of renal cell carcinoma using an integrated staging system

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Direct and indirect effects of human recombinant gamma-interferon on tumor cells in a clonogenic assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/14514977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1385/MO:20:3:271

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/14514977

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/14514977

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47599414&oldid=2208663536"